Member Info for KingHomerJ

Trout…..

Glad to hear you have do ok…and I’m genuinely happy for you as that’s what it’s all about….

I’ve been in PYC and done alright myself…..over the years and years….

As I’m sure you will agree PYC is in a far greater position that it ever has been and Peter Sergent has done a great job over the past 18months as CEO

I’m sure he will be delighted when the market confidence is returned on his watch that correctly as you say as been knocked for 6 by the previous watch….

PYC current situation is a country mile away from where it was 18months ago and that’s evident to see.

I wish you all the success and hope you make significant gains as do we all and fundamentally I’m

Sure we will

Each to their own…

I will ask again ask again….are you aware of the current monthly burn rate….

You have zero idea……because yes you are an amateur…

GL xxx

Your frankly lazy as you can’t even research / google these simple fact….

Do you have broker subscriptions…..guess not…

Do you know the burn rate Yes or NO…….

Trout…..You are wrong…..

Mustn’t have read the broker notes then…. Have you….

Do you know the cash Burn rate YES or NO….its a very simple question to answer its either one or the other…..

I do know the burn rate….

Amateur…..

Oh trout - for clarity I am also aware of the current burn rate… and I stand by my comments that the cash balance current is enough until Q4 2026 - ON current revenues….

Not including any additional contracts (due)

News within Week(s)

Keep your eyes 👀 peeled on that little red DOT…xx

Trout……

Firstly you are incorrect and I think you full well know this….

Do you know the current burn rate per month……? No you don’t……

I suggest you do a little more research on the company, science and sector….

Much love xxx

Trout,

If you calculate cash in bank from Dec 2024 Plus Raise in 2025 vs current burn rate vs contracts won contracted into 2026 & 2027 plus grant revenue...the current burn rate would be into Q4 2026.....

That is of course there isn't any further added costs (payroll etc)

Thank Laura,

I understand the point in pointing out that PYC is undervalued but I'm not interested in other companies as there so many different aspects & variables linked to companies Market Caps.

It's apples and pears in my opinion...

Id focus on the aspects of PYC

“Following the Placing and Retail Offer, the Company’s cash resources are expected to be sufficient to support operations until at least Q4 2026.”

(Physiomics Interim Results, March 2025)

Trout,

If you calculate cash in bank from Dec 2024 Plus Raise in 2025 vs current burn rate vs contracts won contracted into 2026 & 2027 plus grant revenue...the current burn rate would be into Q4 2026.....

That is of course there isn't any further added costs (payroll etc)

Very Logical and very true...

Only point i would state on this one is that the revenue, future revenue, dosing tool software, NHS trial, beyond blood, Dosemerx, biostats revenue arm are way way way down the line and coming to fruition.....more than it ever has been over the last 20 years...... The company is due a huge rerate and only 200k from profitability. Has cash until late 2026 (CURRENT) without any further contracts and has zero debt

The company was trading at a 15Million MC 4years ago with less revenue, less BOB and without the dosing tool having agreements in place for commercialisation and NHS trials.

PYC will Multi Bag...

The end of year results are out this month followed by a company presentation….im sure a lot of things will be clarified….and a good picture on the current traction being made….

The company is only a few contracts away from profitability…..

The Biostats arm of the business is predicted to match the VT revenue

Physiomics is in a markedly better position than earlier:

Record contract wins and £593k of FY26 contracted revenue (plus £98.6k new award and £60k grant) give meaningful revenue visibility.

These revenue commitments appear large enough to cover ~£564k of annual operating burn, providing a surplus runway buffer.

Revised runway now stretches well into late 2026 and potentially into FY27 (early 2027).

This improved liquidity strengthens strategic optionality and reduces near-term funding risks.

This one’s a buy….

Other two are sells by the looks of it

Just my views on cash position as it’s commonly mentioned on this board,

June 2025 Total Income rose by 46%, reaching £834,000 (up from £570,561 in FY24)

Loss after tax reduced by 31% to £419,000 compared to FY24’s £670,816

Secured robust new contract wins, averaging over £1 million per year, and began FY26 with £593,000 of contracted revenue to be recognized in that year — up approximately 19% from the prior year.

Additional £98,600 18-month contract signed recently, plus £60,000 in expected grant income.

Previously Physiomics held approximately £769,000 in cash following:

£269,000 as of December 31, 2024

£500,000 raised in February 2025

This in mind Physiomics appears to be in a healthier position than previously. With £769k in cash, reduced losses, and a solid backlog (£593k) plus new contract/grant income, their operational runway could extend well into FY27, depending on timing of revenues and cost management.

This doesn’t include any further contracts announced - and the company clearly state there is positive momentum….

Quality and Validation

The evaluated software tools fulfilled the quality and validation criteria for 76% (49–92%). DoseMeRx (92%), MwPharm++ (91%), and InsightRX Nova (90%) were three software tools that fulfilled most of the considered criteria.

All software tools with input data storage capability provide database search by patient name, patient identification, drug name, or date. The benchmarking score of easiness in manually data entry criterion was highest in DoseMeRx, InsightRX Nova, and PrecisePK. These software tools provide structured layout and toolbox widgets that assist users in entering data. In addition, they scored highest on global visual appeal.

Hi Trout, (Please see below)

As they stated in the July RNS,

"Following several iterations of software deployment, evaluation and debugging, the Company has successfully implemented its dosing software onto DoseMe's latest platform. This now allows the tool to be made available to clinicians and health care providers on a research-only basis allowing for important human factor evaluation and additional validation data to be generated."

Can you confirm,

1. This was a delay in getting the software implemented onto theDoseMeRX platform, from the original expectation?

Yes, I believe this was a delay similar as this is running alongside the Trial at Blackpool teaching hospital (with doseme) the regulatory approval was delayed but now underway...

2. That if they were only in July started to roll it out to some Physicians on a research only basis for further validation. that this validation period is likely to be a period of 12-18 months, or perhaps more?

As mentioned above the trial and integration are working alongside each other which will generate significant amounts of data - both in NHS teaching hospital and with Doseme - All this data is relevant and will be part of the regulatory approval.

This is a software device not a medical device. In the EU the regulations fall with the MDR which is rather strict. however in the US the regulations are more relaxed and Physiomics is clearly leaning towards this route to market. - The company is however aligning its self for approval on both counts.

Hope this helps

When the validation is complete DoseMerx is a confirmed route to market.

DoseMerx have tens of thousands of licenses across the US and Europe.

The dosing tool would simply be an add onto the software a merely 1% uptake will generate millions in revenue…..and very very very little costs if any at all as this tool has already been going through validation and trials for nearly a decade.